CD34 and acute myeloid leukemia: Additional preclinical studies definitely showed that CSL 362 in vitro induces ADCC-dependent lysis of AML blasts, as well as of LSC-enriched CD34+/CD38−/CD123+ cells and in vivo reduces leukemic cell growth in AML xenografts in immunodeficient mice [120].